0000899243-17-024266.txt : 20171016
0000899243-17-024266.hdr.sgml : 20171016
20171016171606
ACCESSION NUMBER: 0000899243-17-024266
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171013
FILED AS OF DATE: 20171016
DATE AS OF CHANGE: 20171016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SAXE JON S
CENTRAL INDEX KEY: 0001114914
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 171139373
MAIL ADDRESS:
STREET 1: FIRST HORIZON PHARMACEUTICAL CORP
STREET 2: 660 HEMBREE PKWY STE 106
CITY: ROSWELL
STATE: GA
ZIP: 30076
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-13
1
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001114914
SAXE JON S
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
0
0
0
Common Stock
2017-10-13
4
D
0
135000
11.18
D
0
D
Non-Qualified Stock Option (right to buy)
1.75
2017-10-13
4
D
0
30000
9.43
D
2018-06-10
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
2.23
2017-10-13
4
D
0
30000
8.95
D
2019-06-09
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
3.01
2017-10-13
4
D
0
30000
8.17
D
2020-06-10
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
6.04
2017-10-13
4
D
0
30000
5.14
D
2021-06-30
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
6.78
2017-10-13
4
D
0
30000
4.40
D
2022-06-07
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
5.13
2017-10-13
4
D
0
30000
6.05
D
2023-06-27
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
5.10
2017-10-13
4
D
0
30000
6.08
D
2024-06-12
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
9.15
2017-10-13
4
D
0
30000
2.03
D
2025-06-11
Common Stock
30000
0
D
Non-Qualified Stock Option (right to buy)
10.90
2017-10-13
4
D
0
30000
0.28
D
2027-06-08
Common Stock
30000
0
D
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2008), and became immediately exercisable and vested in full as of June 9, 2009.
The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.
/s/ Friedhelm Blobel, Attorney-in-Fact For: Jon S. Saxe
2017-10-16